April 13, 2016
The Food and Drug Administration’s role is to determine a follow-on drug’s biosimilarity to its biologic predecessor, explained FDA’s Steven Kozlowski, MD, at Tuesday’s National Policy & Advocacy Summit on Biologics and Biosimilars.
April 11, 2016
A physician tells a story in the Alliance for Patient Access’ oncology working group white paper about attending the funeral of one of his cancer patients.
April 8, 2016
Patients with respiratory conditions are often not sick enough to be in critical care but not well enough to deal with their symptoms without consistent intervention. So explains a newly released white paper from the Institute for Patient Access and the Alliance for Patient Access’ Respiratory Therapy Access Working Group.
April 7, 2016
Health insurers who deny patients access to hepatitis C cures could be violating federal law, explains an April 5 letter from the Alliance for Patient Access and The AIDS Institute to Florida’s insurance commissioner.
April 6, 2016
The Food and Drug Administration approved the second U.S. biosimilar on Tuesday, clearing the drug for seven different indications.
April 6, 2016
https://www.aarc.org/wp-content/uploads/2013/07/IfPA_Improving-Access-to-Respiratory-Care_April-2016.pdf
April 4, 2016
The Food and Drug Administration has released its long-anticipated draft guidance on biosimilar labeling – but the document may leave some health care providers and patient advocates disappointed.
April 1, 2016
Indiana Governor Mike Pence has signed into law a bill restricting the use of step therapy – following in the footsteps of California, Maryland, New Hampshire and other states that have tackled the issue.
March 29, 2016
Two months have passed since the World Health Organization released its final proposal on naming biological and biosimilar medications.
March 24, 2016
Clinical practice guidelines are intended to optimize patient care, explains a new policy brief from the Institute for Patient Access.
